

CLAIMS

What is claimed is:

5

1. A multifunctional protein molecule comprising at least one decorin molecule having at least 95% sequence identity to SEQ ID NO: 7 linked to an antibody molecule selected from the group consisting of bevacizumab, ranibizumab, ipilimumab, atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab.

10

2. The multifunctional protein molecule of claim 1, wherein the multifunctional protein molecule comprises two or more copies of the decorin molecule.

15

3. The multifunctional protein molecule of claim 1, wherein the decorin molecule is operably linked to a heavy chain of the antibody.

4. The multifunctional protein molecule of claim 1, wherein the multifunctional protein molecule is a fusion protein.

20

5. A nucleic acid or set of nucleic acids encoding a multifunctional protein molecule of claim 1.

6. A vector or vectors comprising the nucleic acid or set of nucleic acids of claim 5.

25

7. A host cell comprising the vector or vectors of claim 6.

8. Multifunctional protein molecule of claim 1 for use in treating a disorder characterized by angiogenesis or tumor growth.

30

9. Use of the multifunctional protein molecule of claim 1 in the manufacture of a medicament for the treatment of a disorder characterized by angiogenesis or tumor growth.

10. The use of claim 9, wherein the tumor is selected from the group consisting of lung cancer, colorectal cancer, liver cancer, breast cancer, kidney cancer, cervical cancer, ovarian cancer, and glioblastoma.